Valor20202021202220232024TTMGastos comerciales, generales y administrativos——————Investigación y desarrollo——————Beneficio operativo——————Total de ingresos no operativos——————Gastos por intereses, netos de intereses capitalizados——————Ingresos no operativos, una vez deducidos los gastos por intereses——————Ingresos/gastos extraordinarios——————Beneficio antes de impuestos——————Participación en los beneficios——————Impuestos——————Participación minoritaria——————Otros ingresos/gastos después de impuestos——————Beneficio neto antes de actividades interrumpidas——————Operaciones suspendidas——————Beneficio neto——————Ajuste por dilución——————Dividendos de las acciones preferentes——————Beneficio neto diluido atribuible a los accionistas——————Beneficio básico por acción——————Beneficio por acción diluido——————Número medio de acciones ordinarias——————Acciones diluidas——————EBITDA——————EBIT——————Costo de los ingresos——————Otros costes de producción——————Amortización y depreciación (flujo de caja)——————
Immuron Limited - American Depositary Shares
Immuron is a biotechnology company based in Melbourne, Australia. In 2008, the company changed its name to Immuron Limited, having previously operated as Anadis Limited.
Immuron is focused on antigen-primed and dairy-derived health products. Its proprietary technologies allow for rapid development of polyclonal antibody and other proteins-based solutions for a range of diseases. The company specialises in nutraceutical, pharmaceutical and therapeutic technology products for conditions such as oral and GI mucositis, avian influenza, E. coli travellers' diarrhoea and Anthrax containment.
In 2005, Anadis signed an agreement with Quebec's Baralex Inc. and Valeo Pharma Inc. for the distribution of Travelan, a product made by Anadis for the Canadian market.